Not yet recruiting
Neuromyelitis optica spectrum disorder+7
Not yet recruitingSafety and dose‑finding study of CD19‑CART01 in patients with SLE, SSc, DM/PM, IMNM, AAV, MG, NMOSD, or chronic GVHD
InvestigationalNo placebo
Safety and dose‑finding study of CD19‑CART01 in patients with SLE, SSc, DM/PM, IMNM, AAV, MG, NMOSD, or chronic GVHD
InvestigationalNo placebo
- Disease:Neuromyelitis optica spectrum disorderSystemic scleroderma+6
- Substances:CD19-CART01
Countries:
Italy
Italy- Participants:0–17 years · 18–64 years · 65+ years
- Substances:CD19-CART01
